ReviewCurrent neuropharmacology2019
Pharmacological Treatment of Body Dysmorphic Disorder.
Review in Current neuropharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 2 syntheses or guidelines pooled it, 42 citations in OpenAlex.
- Effects of Pharmacological and Psychological Treatments on Depressive Symptoms in Body Dysmorphic Disorder: A Systematic Review and Meta-Analysis.Current psychiatry reports · 2026Pooled it
- Prevalence of Body Dysmorphic Disorder: A Systematic Review and Meta-Analysis.Journal of cosmetic dermatology · 2025Pooled it
- Prevalence of body dysmorphic disorder, gender differences and association with body mass index among medical students in Pakistan.Discover mental health · 2025Article
- Exploring the Prevalence and Etiological Factors of Body Dysmorphic Disorder in Cosmetic Surgery Populations: Implications for Enhanced Clinical Assessment.Aesthetic plastic surgery · 2025Article
- Body Dysmorphic Disorder and Risperidone Abuse: Exploiting Hyperprolactinemia.Journal of the Korean Academy of Child and Adolescent Psychiatry · 2025Article
- Risk of self-harm in patients with body dysmorphic disorder: a population-based cohort study.Frontiers in psychiatry · 2025Article
- Body Dysmorphic Disorder and Self-esteem in Adolescents and Young Adults with Acne Vulgaris.Acta dermato-venereologica · 2023Article
- A review of psychocutaneous disorders from a psychotherapeutic perspective-Toolkit for the dermatologist.Skin health and disease · 2023Review
- Are YouTube videos a reliable source of information about body dysmorphic disorder?Postepy psychiatrii neurologii · 2023Article
- Somatization in dermatology.Skin health and disease · 2022Review
- Early response to cognitive behavioral therapy for body dysmorphic disorder as a predictor of outcomes.Journal of psychiatric research · 2022Article
- Body dysmorphic disorder and depression among male undergraduate students in a Malaysian University.Frontiers in psychiatry · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Body dysmorphic disorder is a challenging disorder that manifests as erroneously perceived flaws in one's physical appearance and repetitive behaviors in response to appearance concerns. This disorder is also frequently comorbid with other psychiatric disorders, including major depressive disorder and autism spectrum disorder. It is currently understood to arise from a combination of biological, psychological, and environmental factors. Treatment of body dysmorphic disorder typically consists of a combination of pharmacotherapy and cognitive behavioral therapy. However, not all patients respond to treatment, and BDD symptoms remain even in those who do respond. This review outlines current pharmacological and neuromodulation treatments for body dysmorphic disorder and suggests directions for future studies of novel treatments such as augmentation with atypical antipsychotics and the use of intranasal oxytocin in cases of body dysmorphic disorder that show residual symptomatology even with tailored monotherapy. There is emerging evidence suggesting that non-invasive neurostimulatory techniques, such as repetitive transcranial magnetic stimulation, may be of value in treatment-resistant cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.